Assessing patient preference in migraine treatment

被引：12

作者：

Dahlöf, C ^{[1
]}

机构：

[1] Sociala Huset, Gothenburg Migraine Clin, Gothenburg, Sweden

来源：

CEPHALALGIA | 2001年 / 21卷 / 08期

关键词：

D O I：

10.1046/j.1468-2982.2001.00256.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：791 / 795

页数：5

共 8 条

[1] How to assess patient preference of migraine treatments [J].

Dahlöf, C .

CEPHALALGIA, 1999, 19 :2-6

[2]

DAHLOF C, 2000, HEADACHES, P43

[3]

DAHLOF C, 2001, CEPHALALGIA, V21, P410

[4]

DAHLOF C, 2001, IN PRESS CEPHALALGIA, P21

[5]

DAHLOF C, 2001, IN PRESS CURRENT MED, P17

[6] Effect of encapsulation on absorption of sumatriptan tablets: Data from healthy volunteers and patients during a migraine [J].

Fuseau, E ;

Petricoul, O ;

Sabin, A ;

Pereira, A ;

O'Quinn, S ;

Thein, S ;

Leibowitz, M ;

Purdon, H ;

McNeal, S ;

Salonen, R ;

Metz, A .

CLINICAL THERAPEUTICS, 2001, 23 (02) :242-251

[7] An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients [J].

Pascual, J ;

Muñoz, R ;

Leira, R .

CEPHALALGIA, 2001, 21 (06) :680-684

[8] Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine [J].

Pascual, J ;

Bussone, G ;

Hernandez, JF ;

Allen, C ;

Vrijens, F ;

Patel, K .

EUROPEAN NEUROLOGY, 2001, 45 (04) :275-283

← 1 →